Overview

Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to show non-inferiority of a CNI-free regimen with respect to the renal function at Month 9 post Tx assessed by glomerular filtration rate - Nankivell method - as compared to the standard CNI-based regimen in de novo renal transplant patients.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Basiliximab
Everolimus
Mycophenolate mofetil
Mycophenolic Acid
Sirolimus
Tacrolimus